Stocks● Neutral
FDA Grants Priority Review to Praxis Precision Medicines Pipeline
Relutrigine moves closer to market as the FDA accepts New Drug Applications. Investors should monitor clinical catalysts scheduled to unfold through 2027.
Continue with
Praxis Precision Medicines, Inc. has reached a significant milestone as the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Applications (NDAs) for relutrigine. The regulatory body has granted priority review for the candidate, highlighting its potential impact on current treatment landscapes.
This development serves as a cornerstone for the company’s broader clinical strategy. Praxis is currently positioning its developmental pipeline to address developmental and epileptic encephalopathies (DEE), with a series of key data readouts and clinical catalysts scheduled to unfold through 2027. The acceptance of these applications marks an essential step in the company’s efforts to bring its precision medicine therapies to market, reinforcing its commitment to neurological research and long-term expansion within the specialty pharmaceutical sector.